Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces its commitment to expand the availability of RefluxStop and training of new centers across Europe and the UK in view of the recent announcement to withdraw the LINX Reflux Management System from the European market effective March 31, 2026, as reported across many media outlets.

Dr. Peter Forsell, Implantica's founder, CEO, and the inventor of RefluxStop, says, "We are 100 per cent devoted to serving reflux patients, as well as the surgeons and gastroenterologists dedicated to their care, with the state-of-the-art RefluxStop device. With more than 1400 patients treated, excellent long-term clinical outcomes, and over 45 centers of excellence established across Europe, RefluxStop is very well positioned to fill the upcoming treatment gap as our main device competitor exits the European market. I believe the groundbreaking design and strong clinical potential of RefluxStop will make it a true game-changer for the many hundreds of millions of people suffering from acid reflux in Europe and worldwide."